Vemurafenib resistance reprograms melanoma cells towards glutamine dependence

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Hernandez Davies, Jenny E ^a   Tran, Thai Q ^a   Reid, Michael A ^a   Rosales, Kimberly R ^a   Lowman, Xazmin H ^a   Pan, Min ^a   Moriceau, Gatien ^b   Yang, Ying ^a   Wu, Jun ^a   Lo, Roger S ^b   Kong, Mei ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

V600; BPTES; BRAF; Cancer metabolism; Glutamine; L DON; Melanoma; NRAS; Vemurafenib resistance

Indexed keywords

6 DIAZO 5 OXONORLEUCINE; GLUTAMINE; HYDROLASE INHIBITOR; SELUMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; [BIS 2 (5 PHENYLACETAMIDO 1,2,4 THIADIAZOL 2 YL)ETHYL SULFIDE]; ENZYME INHIBITOR; GLUTAMINASE; GUANOSINE TRIPHOSPHATASE; INDOLE DERIVATIVE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; SULFONAMIDE;

AMINO ACID METABOLISM; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CELL SURVIVAL; CELLS BY BODY ANATOMY; CONTROLLED STUDY; DRUG DOSE TITRATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; ONCOGENE N RAS; SENSITIVITY ANALYSIS; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE SILENCING; METABOLISM; NONOBESE DIABETIC MOUSE; NUCLEAR REPROGRAMMING; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELLULAR REPROGRAMMING; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE KNOCKDOWN TECHNIQUES; GLUTAMINASE; GLUTAMINE; GTP PHOSPHOHYDROLASES; HUMANS; INDOLES; MELANOMA; MEMBRANE PROTEINS; MICE, INBRED NOD; MICE, SCID; SULFONAMIDES;

EID: 84934277617     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0581-2     Document Type: Article

References (33)

1. Bucheit AD, Davies MA (2014) Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol 87(3):381-389. doi: 10.1016/j.bcp.2013.11.013
2. American Cancer Society FaF (2014) Facts and figures 2014
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949-954. doi: 10.1038/nature00766
4. Sondergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S et al (2010) Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 8:39. doi: 10.1186/1479-5876-8-39
5. Shi H, Kong X, Ribas A, Lo RS (2011) Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 71(15):5067-5074. doi: 10.1158/0008-5472.CAN-11-0140
6. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R et al (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15(3):323-332. doi: 10.1016/S1470-2045(14)70012-9
7. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358-365. doi: 10.1016/S0140-6736(12)60868-X
8. Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A et al (2014) Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol 15(9):954-965. doi: 10.1016/S1470-2045(14)70301-8
9. Queirolo P, Picasso V, Spagnolo F (2015) Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Cancer Treat Rev. doi: 10.1016/j.ctrv.2015.04.010
10. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372(1):30-39. doi: 10.1056/NEJMoa1412690
11. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694-1703. doi: 10.1056/NEJMoa1210093
12. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H et al (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326):973-977. doi: 10.1038/nature09626
13. Spagnolo F, Ghiorzo P, Orgiano L, Pastorino L, Picasso V, Tornari E et al (2015) BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Therapy 8:157-168. doi: 10.2147/OTT.S39096
14. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G et al (2014) Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642
15. DeBerardinis RJ, Cheng T (2010) Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29(3):313-324. doi: 10.1038/onc.2009.358
16. Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR et al (2014) Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov 4(4):423-433. doi: 10.1158/2159-8290.CD-13-0440
17. Wise DR, Thompson CB (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35(8):427-433. doi: 10.1016/j.tibs.2010.05.003
18. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M et al (2013) Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496(7443):101-105. doi: 10.1038/nature12040
19. Wang Q, Beaumont KA, Otte NJ, Font J, Bailey CG, van Geldermalsen M et al (2014) Targeting glutamine transport to suppress melanoma cell growth. Int J Cancer J Int du Cancer 135(5):1060-1071. doi: 10.1002/ijc.28749
20. Kisner DL, Catane R, Muggia FM (1980) The rediscovery of DON (6-diazo-5-oxo-l-norleucine). Recent Results Cancer Res 74:258-263
21. Sklaroff RB, Casper ES, Magill GB, Young CW (1980) Phase I study of 6-diazo-5-oxo-l-norleucine (DON). Cancer Treat Rep 64(12):1247-1251
22. Thangavelu K, Chong QY, Low BC, Sivaraman J (2014) Structural basis for the active site inhibition mechanism of human kidney-type glutaminase (KGA). Sci Rep 4:3827. doi: 10.1038/srep03827
23. Shukla K, Ferraris DV, Thomas AG, Stathis M, Duvall B, Delahanty G et al (2012) Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem 55(23):10551-10563. doi: 10.1021/jm301191p
24. Thangavelu K, Pan CQ, Karlberg T, Balaji G, Uttamchandani M, Suresh V et al (2012) Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc Natl Acad Sci USA 109(20):7705-7710. doi: 10.1073/pnas.1116573109
25. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J et al (2012) Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 15(1):110-121. doi: 10.1016/j.cmet.2011.12.009
26. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV et al (2010) Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 70(22):8981-8987. doi: 10.1158/0008-5472.CAN-10-1666
27. Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, Hamilton SK et al (2007) Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J 406(3):407-414. doi: 10.1042/BJ20070039
28. Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC et al (2015) Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 27(2):240-256. doi: 10.1016/j.ccell.2014.11.018
29. Keshelava N, Frgala T, Krejsa J, Kalous O, Reynolds CP (2005) DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 110:139-153. doi: 10.1385/1-59259-869-2:139
30. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516. doi: 10.1056/NEJMoa1103782
31. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107-114. doi: 10.1056/NEJMoa1203421
32. Homet Moreno B, Parisi G, Robert L, Ribas A (2015) Anti-PD-1 therapy in melanoma. Semin Oncol 42(3):466-473. doi: 10.1053/j.seminoncol.2015.02.008
33. Queirolo P, Morabito A, Laurent S, Lastraioli S, Piccioli P, Ascierto PA et al (2013) Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study. Cancer Invest 31(5):336-345. doi: 10.3109/07357907.2013.793699